Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adult companion dogs allocate social proximity toward owners over household dogs under competing contexts.

Animal cognition·2026
Same author

Early life bacteria and sibling exposure associate with restoration of the infant gut microbiome after cesarean section.

Nature communications·2026
Same author

The Emergence of Belief Attribution and Dehumanization Are Associated.

Developmental science·2026
Same author

Associations between early-life exposures and the infant skin microbiome.

The British journal of dermatology·2026
Same author

Tolerance as a key mechanism for large-scale social cohesion.

The Behavioral and brain sciences·2025
Same author

Chimpanzees are natural scientists.

Science (New York, N.Y.)·2025
Same journal

Safety and efficacy of deltoid intramuscular long-acting cabotegravir and rilpivirine, a case series.

Antiviral therapy·2026
Same journal

Factors associated with immunological non-response in HIV patients receiving antiretroviral therapy in Southeast Asia: A systematic review.

Antiviral therapy·2026
Same journal

Epidemiology and clinical management of cytomegalovirus infection in transplant recipients in Central and Eastern Europe - a physician survey.

Antiviral therapy·2026
Same journal

It's about time: The association between abacavir and cardiovascular disease.

Antiviral therapy·2026
Same journal

Combination antiviral and anti-CMV immunoglobulin therapy for CMV infection: A case-control study.

Antiviral therapy·2026
Same journal

Harnessing SuperNatural database to identify VP35 inhibitors as anti-Ebola drug candidates: A multistage <i>In silico</i> study.

Antiviral therapy·2025
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Rapid decrease of wild-type hepatitis C virus on telaprevir treatment.

Bambang S Adiwijaya1, Brian Hare, Paul R Caron

  • 1Vertex Pharmaceuticals, Inc., Cambridge, MA, USA.

Antiviral Therapy
|July 7, 2009
PubMed
Summary
This summary is machine-generated.

Telaprevir (TVR) significantly improved hepatitis C virus (HCV) reduction compared to interferon (IFN). TVR-based regimens show potential for faster viral decline and shorter treatment durations in chronic HCV genotype 1 infections.

More Related Videos

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Experiment Videos

Last Updated: Jun 21, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Area of Science:

  • Hepatology
  • Virology
  • Pharmacodynamics

Background:

  • Telaprevir (TVR) is an NS3.4A protease inhibitor for hepatitis C virus (HCV) genotype 1.
  • Antiviral activity of TVR was compared to interferon (IFN)-based treatments.

Purpose of the Study:

  • To quantify viral dynamics in HCV genotype 1 patients treated with TVR monotherapy or combination therapy.
  • To compare the efficacy of TVR-based regimens against historical IFN treatment data.

Main Methods:

  • A biphasic viral dynamic model was used to analyze viral kinetics.
  • Data from 36 patients on TVR monotherapy and 8 on TVR plus pegylated interferon (PEG-IFN)-alpha2a were analyzed.

Main Results:

  • TVR-based regimens achieved a median second-phase viral decrease of 1.1 per day, approximately 10-fold higher than IFN.
  • Higher TVR dosage correlated with improved viral blockage in monotherapy patients.
  • Combination therapy showed a median remaining viral production of -2.37 log(10) after blockage.

Conclusions:

  • TVR-based regimens promote rapid early viral decline in chronic HCV genotype 1.
  • These regimens may enhance sustained viral response rates.
  • TVR offers potential for reduced treatment duration in HCV management.